Targeted Therapy in Lung Cancer

@inproceedings{Schmid2013TargetedTI,
  title={Targeted Therapy in Lung Cancer},
  author={Katharina Schmid},
  year={2013}
}
8 9 More importantly, Rosell et al. and Zhou et al. investigated in two randomized trials (OPTIMAL and EURTAC OPTIMAL study) erlotinib monotherapy versus chemotherapy as first-line treatment in patients with advanced NSCLC and EGFR-mutation in Caucasian and Asian patients, respectively. In both studies a significant progression-free survival benefit over standard chemotherapy with 63% and 84% reduction in risk of progression was found (HR 0.37 and HR 0.16). A significant quality of life benefit… CONTINUE READING